Beat the Nasdaq With This Cash-Gushing Dividend Stock
Reliable dividend income from high-quality companies is a great option for investors seeking to ride out stock market turbulence. Biotech giant (NASDAQ: AMGN) exemplifies this strategy with its 3.3% dividend yield, supported by steady growth and rock-solid fundamentals. Compared to an 8% decline in the Nasdaq Composite index year to date, Amgen stock has outperformed, up 9% thus far in 2025.
Let's explore why this cash-generating healthcare leader is well-positioned to continue beating the Nasdaq.
The biopharmaceutical industry is one of the most vital sectors in the economy, developing groundbreaking medicines that can be life-changing for patients fighting serious diseases. Amgen stands out with a highly diversified portfolio of over 40 therapeutics across four key areas -- General Medicine, Rare Disease, Inflammation, and Oncology. Notably, 14 of its products have achieved blockbuster status, generating over $1 billion in annualized sales with best-in-class profiles.
Source Fool.com
Amgen Inc. Aktie
Die Community bevorzugt Amgen Inc., mit deutlich mehr Buy- (26) als Sell-Einschätzungen (4).
Das von der Community festgelegte Kursziel von 296 € für Amgen Inc. deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 277.75 € hin.
